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Circulating Tumor Cells: Are They Capable of Metastasizing?
It is generally assumed that the detection of tumor cells in the blood of patients with non-hematological malignancies
signifies a high probability of metastasis and unfavorable prognosis. Yet little information is available on the functional
capabilities of circulating cells released from solid organ malignancies. Me´hes et al (Am J Pathol 2001, 159:17–20)
analyzed circulating breast cancer cells to determine whether those cells might be apoptotic. The cells were identified
by automated fluorescence image analysis using cytokeratin (CK) and epithelial-type mucin (MUC1) as markers. These
cells were detectable in 42% of blood samples from breast cancer patients but not in 25 patients who served as a control
group. Apoptosis was assessed by changes in staining patterns of the CK marker, chromatin fragmentation and TUNEL
positivity. With the exception of samples from one patient, the majority of circulating cells from breast cancer patients had
an apoptotic phenotype. In 37.5% of peripheral blood samples in which circulating tumor cells were detectable, no intact
cells were found. This work raises the possibility that a large proportion of circulating tumor cells released from
non-hematological malignancies may not be viable and capable of establishing metastatic growth.
Down-Regulation of the Expression of Estrogen Receptor  during Prostatic Carcinogenesis but
not in Metastatic Sites
Most prostate cancers are initially responsive to anti-androgens but often become refractory to this type of therapy.
Estrogens act on target tissues by binding to two types of receptors, ER and ER, which appear to mediate different
downstream activities in prostate tissues. There are also indications that ER is the predominant receptor in the prostate
and that anti-estrogens may inhibit prostatic cell proliferation by interfering with ER signaling. Leav et al (Am J Pathol
2001, 159:79–92) developed specific antibodies to ER and compared the expression of this receptor to that of ER as
well as the androgen receptor in normal dysplastic lesions and carcinomas in the human prostate. They also measured
receptor transcripts by reverse transcriptase-polymerase chain reaction using tissue samples obtained by laser capture
microdissection. ER was found to be predominantly localized in basal cells while ER was mostly localized in stromal
cells. ER- expression was down-regulated during prostatic carcinogenesis in high-grade dysplastic lesions and
high-grade neoplasias. Surprisingly, ER was expressed in the great majority of prostate cancer metastases in bone and
lymph nodes. The new knowledge gained by studies on ER will help improve the treatment of prostate cancer with
agents that act on specific estrogen receptors.
Loss of 10q and PTEN in Anaplastic Oligodendrogliomas: Poor Prognosis Even with Response
to Chemotherapy
Allelic loss of chromosome 10q is one of the most frequent alterations in gliomas. It has been detected in approximately
80% of glioblastomas, 37 to 75% of anaplastic astrocytomas, and 13 to 31% of anaplastic oligodendrogliomas. The 10q
loss in malignant gliomas may involve three potential tumor suppressor genes: PTEN, DMBT1, and ERCC6. Sasaki et al
(Am J Pathol 2001, 159:359–367) analyzed these three genes in a large number of patients with anaplastic oligoden-
drogliomas. Deletion mapping demonstrated 10q loss in 14 of 67 cases with the PTEN and DMBT1 region involved in all
deletions. PTEN gene alterations were not associated with a poor response to chemotherapy, but were independent
predictors of poor prognosis even in tumors that responded to chemotherapy.
Epidermal Hypertrophy, Hyperplasia, and Dermal Fibrosis Caused by Increased Expression of
Cyclin-Dependent Kinase 4 (CDK4)
Progression through the G1 phase of cell cycle is regulated by cyclins and their associated kinases (CDKs). Members
of the cyclin D family (D1, D2 and D3) can form complexes with CDK4 which is partially responsible for the phosphor-
ylation of the retinoblastoma gene (Rb) and its subsequent inactivation. Rb phosphorylation releases the inhibition of
transcription factors and other genes involved in the G1-S cell cycle transition. It is known that cyclins D1 and D2 have
profound effects on cell proliferation and tumor development in various tissues. However, much less is known about the
role that CDK4 by itself might have on cell cycle regulation. To study this problem, Miliani de Marval et al (Am J Pathol
2001, 159:369–379) developed transgenic mice that overexpressed CDK4 in the epidermis under the control of a keratin
5 promoter. These mice had increased epidermal proliferation with basal cell hypertrophy and hyperplasia. Overall, these
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abnormalities were much more extensive than those observed in transgenic mice that overexpress D-type cyclins. In
addition, the CDK4 transgenics had severe dermal fibrosis and atrophy of subcutaneous adipose tissue. Increased
expression of CDK4 did not alter the level of expression of D-type cyclins but most likely stimulated epidermal
proliferation by binding and sequestering the cell cycle inhibitor p27. The results demonstrate that CDK4 can act
independently from cyclins to stimulate cell proliferation by binding cell cycle inhibitors. Moreover, hyperproliferative
epidermis may release growth factors that act to promote dermal fibrogenesis.
Alterations in TGF-1 Signaling in Myofibroblasts from Fibrotic Skin: Impairment of Smad3
Signaling
TGF-1 is a multifunctional cytokine that can inhibit cell growth, stimulate the deposition of collagen and extracellular
matrix components, and act as an immune suppressor. The mechanisms that determine TGF-1 effects on cell
proliferation and fibrogenesis are not completely understood. Reisdorf et al (Am J Pathol 2001, 159:263–272) studied
TGF-1 response in myofibroblasts obtained from fibrotic skin from pigs treated with  radiation. Myofibroblasts from
these tumors showed a dissociation between the proliferative and fibrogenic effects of TGF-1. In contrast to its effect
on normal skin fibroblasts, TGF-1 did not inhibit proliferation of myofibroblasts. In addition, translocation of Smad3, one
of the TGF- receptor-activated proteins, was greatly impaired in myofibroblasts. The results suggest that signaling
through Smad3 is required for TGF-1 effects on cell proliferation but not for its fibrogenic activity.
Circulating Endostatin Released from the Liver Can Block Ocular Neovascularization
Neovascularization involves an imbalance between stimulators and inhibitors of endothelial cell growth. It is now
recognized that endothelial cells in various tissues may differ in their phenotypic characteristics and may react differently
to stimulators and inhibitors. Neovascularization plays an important role in diabetic retinopathy. Furthermore, choroidal
neovascularization is responsible for severe visual loss in patients with age-related macular degeneration, a very
common cause of visual impairment in patients over 60 years of age. The retina and choroid are highly specialized
tissues with unique vasculatures that make it difficult to predict their response to inhibitors of neovascularization. Mori et
al (Am J Pathol 2001, 159:313–320) demonstrate that circulating endostatin can nearly completely prevent choroid
neovascularization in mice. In these experiments, mice were injected intravenously with adenovirus vectors containing
a sequence coding for murine endostatin. These vectors localized primarily in the liver which became the source of
circulating endostatin reaching levels which were approximately 10 times higher than normal. In these animals,
circulating endostatin prevented choroidal neovascularization caused by laser photocoagulation and rupture of Bruch
membrane. The work demonstrates that it is possible to inhibit ocular neovascularization by systemic administration of
protein inhibitors contained in vectors that lodge in the liver.
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